AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research
This article was originally published in PharmAsia News
Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.
You may also be interested in...
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.